HC Wainwright & Co. Reiterates Buy on Arcturus Therapeutics, Maintains $51 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Ed Arce has reiterated a Buy rating on Arcturus Therapeutics (NASDAQ:ARCT) and maintained a price target of $51.
November 15, 2023 | 3:37 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Ed Arce has reiterated a Buy rating on Arcturus Therapeutics and maintained a $51 price target.
The reiteration of a Buy rating and the maintenance of a $51 price target by a reputable analyst could lead to increased investor confidence in Arcturus Therapeutics, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100